Aurinia Pharmaceuticals Inc.
9.20%
12,229,500
1600620
05156V102
Feb 26, 2026
Mar 3, 2026, 05:30 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | Other | 9.20% | 12,229,500 | 0 | 12,229,500 |
| KEVIN TANG | Individual | 9.20% | 12,229,500 | 0 | 12,229,500 |
| TANG CAPITAL PARTNERS, LP | Partnership | 5.30% | 6,990,461 | 0 | 6,990,461 |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | Partnership | 3.90% | 5,239,039 | 0 | 5,239,039 |
| TANG CAPITAL PARTNERS III, INC | CO | 0.00% | 0 | 0 | 0 |
| TANG CAPITAL PARTNERS IV, INC | CO | 0.00% | 0 | 0 | 0 |
Disclosure Items (4)
Common Shares, no par value
Aurinia Pharmaceuticals Inc.
#140, 14315 - 118 Avenue, Edmonton, A0, T5L 4S6
Item 3 of the Original Schedule 13D is hereby amended to add the following: Since March 4, 2025 the Reporting persons have expended an aggregate of approximately $26.3 million to purchase 2,200,000 of the Issuer's Common Shares through the open market. The Common Shares were acquired in the ordinary course of business.
The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 12,229,500 of the Issuer's Common Shares, representing 9.2% of the outstanding shares.
See item 5(a) above.
Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Common Shares that were effected during the past 60 days by the Reporting Persons.
No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Shares beneficially owned by the Reporting Persons.
Not applicable
Exhibit 1: Joint Filing Agreement by and among the Reporting Persons (filed as Exhibit 1 of the 13D filed on March 4, 2025 by the Reporting Persons with respect to the Common Shares of the Issuer). Exhibit 2: Schedule A: Transactions during the past 60 days (as amended).